Pathogenesis of myeloma bone disease

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalLeukemia
Volume23
Issue number3
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Bone Diseases
Multiple Myeloma
Bone and Bones
Neoplasms
Spontaneous Fractures
Hypercalcemia
Bone Resorption
Tumor Burden
Osteoblasts
Osteogenesis
Neoplasm Metastasis
Pain

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Pathogenesis of myeloma bone disease. / Roodman, G. David.

In: Leukemia, Vol. 23, No. 3, 2009, p. 435-441.

Research output: Contribution to journalArticle

Roodman, G. David. / Pathogenesis of myeloma bone disease. In: Leukemia. 2009 ; Vol. 23, No. 3. pp. 435-441.
@article{2ccd437d2dc1426b8ea4f3fec70a5edb,
title = "Pathogenesis of myeloma bone disease",
abstract = "Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50{\%} in a local area, osteoblast activity is either suppressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.",
author = "Roodman, {G. David}",
year = "2009",
doi = "10.1038/leu.2008.336",
language = "English (US)",
volume = "23",
pages = "435--441",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pathogenesis of myeloma bone disease

AU - Roodman, G. David

PY - 2009

Y1 - 2009

N2 - Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.

AB - Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article.

UR - http://www.scopus.com/inward/record.url?scp=62549117773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549117773&partnerID=8YFLogxK

U2 - 10.1038/leu.2008.336

DO - 10.1038/leu.2008.336

M3 - Article

C2 - 19039321

AN - SCOPUS:62549117773

VL - 23

SP - 435

EP - 441

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -